(NASDAQ: SLXN) Silexion Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.06%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.47%.
Silexion Therapeutics's earnings in 2026 is -$16,380,000.On average, 4 Wall Street analysts forecast SLXN's earnings for 2026 to be -$1,760,785, with the lowest SLXN earnings forecast at -$1,868,299, and the highest SLXN earnings forecast at -$1,623,396. On average, 3 Wall Street analysts forecast SLXN's earnings for 2027 to be -$953,046, with the lowest SLXN earnings forecast at -$915,672, and the highest SLXN earnings forecast at -$981,077.
In 2028, SLXN is forecast to generate -$1,141,091 in earnings, with the lowest earnings forecast at -$1,096,342 and the highest earnings forecast at -$1,174,652.